Profile data is unavailable for this security.
About the company
Gain Therapeutics, Inc. is a biotechnology company. The Company is focused on developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company’s drug discovery platform, Magellan discovers novel allosteric binding sites on proteins implicated in a disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Its lead product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease, including restoration of glucocerebrosidase or GCase, function in the lysosome, reduction of toxic lipid substrates and toxic forms of alpha-synuclein, improved survival of dopaminergic neurons, and enhance in dopamine levels.
- Revenue in USD (TTM)0.00
- Net income in USD-19.39m
- Incorporated2020
- Employees23.00
- LocationGain Therapeutics Inc4800 Montgomery Lane, Suite 220BETHESDA 20814United StatesUSA
- Phone+1 (301) 500-1556
- Fax+1 (302) 655-5049
- Websitehttps://www.gaintherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Annovis Bio Inc | 0.00 | -24.88m | 62.81m | 8.00 | -- | 3.64 | -- | -- | -1.41 | -1.41 | 0.00 | 0.6517 | 0.00 | -- | -- | 0.00 | -157.74 | -116.87 | -221.93 | -138.75 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 56.25 | -- | -- | -- |
| Fractyl Health Inc | 3.00k | -122.20m | 64.17m | 107.00 | -- | -- | -- | 21,390.29 | -2.27 | -2.27 | 0.00006 | -0.024 | 0.00002 | -- | -- | 28.04 | -101.33 | -78.52 | -118.18 | -97.44 | 100.00 | -- | -4,073,233.00 | -122,747.90 | -- | -31.40 | 1.12 | -- | -22.50 | -- | 25.29 | -- | 78.65 | -- |
| Adicet Bio Inc | 0.00 | -115.01m | 66.19m | 152.00 | -- | 0.3294 | -- | -- | -20.22 | -20.22 | 0.00 | 20.98 | 0.00 | -- | -- | 0.00 | -59.52 | -36.24 | -66.08 | -39.41 | -- | -- | -- | -813.80 | -- | -- | 0.0088 | -- | -- | -- | 17.90 | -- | 32.77 | -- |
| Gain Therapeutics Inc | 0.00 | -19.39m | 69.62m | 23.00 | -- | 11.02 | -- | -- | -0.6364 | -0.6364 | 0.00 | 0.1643 | 0.00 | -- | -- | 0.00 | -153.07 | -79.58 | -234.03 | -95.32 | -- | -- | -- | -19,975.78 | -- | -33.79 | 0.067 | -- | -100.00 | -- | 8.34 | -- | 10.39 | -- |
| Coeptis Therapeutics Holdings Inc | 500.99k | -11.28m | 69.78m | 5.00 | -- | 6.03 | -- | 139.29 | -3.47 | -3.47 | 0.1476 | 2.01 | 0.0433 | -- | 11.65 | 100,198.00 | -118.13 | -42.24 | -167.86 | -44.32 | 72.96 | -- | -2,727.81 | -- | -- | -73.66 | 0.0224 | -- | -- | -- | 53.85 | -- | -- | -- |
| Spruce Biosciences Inc | 697.00k | -47.88m | 70.95m | 9.00 | -- | 6.94 | -- | 101.80 | -84.64 | -84.64 | 1.22 | 9.56 | 0.0173 | -- | -- | 33,190.48 | -119.08 | -43.45 | -161.94 | -49.92 | -- | -- | -6,869.30 | -1,459.77 | -- | -353.48 | 0.091 | -- | -51.32 | -- | -10.68 | -- | -- | -- |
| Maia Biotechnology Inc | 0.00 | -22.34m | 71.10m | 13.00 | -- | 1,587.38 | -- | -- | -0.7504 | -0.7504 | 0.00 | 0.0012 | 0.00 | -- | -- | 0.00 | -212.50 | -208.29 | -602.02 | -373.18 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -17.61 | -- | -- | -- |
| Medicinova Inc | 257.92k | -12.01m | 72.74m | 13.00 | -- | 1.65 | -- | 282.01 | -0.2449 | -0.2449 | 0.0053 | 0.8964 | 0.0049 | -- | -- | 19,840.00 | -22.73 | -15.56 | -24.08 | -16.17 | -- | -- | -4,656.61 | -1,144.98 | -- | -- | 0.00 | -- | -100.00 | -- | -28.91 | -- | -39.68 | -- |
| XBiotech Inc | 0.00 | -29.16m | 74.69m | 88.00 | -- | 0.4471 | -- | -- | -0.9566 | -0.9566 | 0.00 | 5.48 | 0.00 | -- | -- | 0.00 | -15.25 | -7.74 | -16.08 | -8.02 | -- | -- | -- | -187.68 | -- | -- | 0.00 | -- | -- | -- | -56.90 | -- | 44.92 | -- |
| Seres Therapeutics Inc | 351.00k | 5.39m | 76.62m | 103.00 | 14.38 | 1.70 | 7.93 | 218.30 | 0.5892 | 0.5892 | 0.0404 | 4.99 | 0.0022 | -- | -- | 3,407.77 | 3.35 | -42.44 | 4.59 | -55.22 | -- | -- | 1,536.75 | -367.23 | -- | -- | 0.00 | -- | -- | -- | 33.85 | -- | -17.63 | -- |
| Ibio Inc | 500.00k | -20.11m | 76.69m | 20.00 | -- | 0.8024 | -- | 153.37 | -1.44 | -1.44 | 0.0232 | 2.77 | 0.0113 | -- | 15.38 | 25,000.00 | -45.35 | -30.90 | -50.81 | -37.76 | -- | -- | -4,021.60 | -2,374.12 | -- | -- | 0.0127 | -- | 77.78 | -24.57 | -19.00 | -- | -57.50 | -- |
| Nuo Therapeutics Inc | 2.61m | -2.43m | 77.25m | -- | -- | -- | -- | 29.58 | -0.0517 | -0.0517 | 0.0555 | -0.0088 | 1.43 | 4.19 | 5.32 | -- | -133.29 | -121.45 | -289.99 | -243.05 | 70.38 | 78.52 | -93.06 | -424.19 | 1.00 | -17,110.33 | -- | -- | 124.34 | 56.34 | 26.73 | -- | -- | -- |
| ImageneBio Inc | 0.00 | -46.14m | 77.27m | 15.00 | -- | 0.5526 | -- | -- | -8.11 | -8.11 | 0.00 | 12.51 | 0.00 | -- | -- | 0.00 | -29.23 | -29.58 | -31.29 | -33.67 | -- | -- | -- | -407.25 | -- | -- | 0.00 | -- | -100.00 | -- | 27.77 | -- | -- | -- |
| Tenax Therapeutics Inc | 0.00 | -43.33m | 78.98m | 4.00 | -- | 0.7767 | -- | -- | -1.13 | -1.13 | 0.00 | 16.29 | 0.00 | -- | -- | 0.00 | -42.77 | -99.65 | -44.80 | -118.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -128.28 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to Gain Therapeutics Inc's reporting currency: US Dollar USD
13.63%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Marshall Wace LLPas of 31 Dec 2025 | 1.66m | 4.32% |
| Edward D. Jones & Co. LP (Investment Management)as of 30 Sep 2025 | 676.82k | 1.76% |
| Cambridge Investment Research Advisors, Inc.as of 31 Dec 2025 | 568.65k | 1.48% |
| DME Capital Management LPas of 30 Sep 2025 | 566.13k | 1.47% |
| Geode Capital Management LLCas of 31 Dec 2025 | 397.94k | 1.04% |
| Citadel Securities LLCas of 30 Sep 2025 | 373.16k | 0.97% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 371.15k | 0.97% |
| Jane Street Capital LLCas of 31 Dec 2025 | 242.33k | 0.63% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 203.07k | 0.53% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 180.38k | 0.47% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
